Cite
Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial
MLA
Qi Yang, et al. “Toripalimab plus Intensity-Modulated Radiotherapy for Recurrent Nasopharyngeal Carcinoma: An Open-Label Single-Arm, Phase II Trial.” Journal for ImmunoTherapy of Cancer, vol. 9, no. 11, Nov. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....848e5f2ea76b4892f9bc4910a90c71ee&authtype=sso&custid=ns315887.
APA
Qi Yang, Yan-Feng Ouyang, Si-Yuan Chen, Yong-Long Liu, Meng-Xia Zhang, Chong-yang Duan, Ming-Yuan Chen, Chenmei Gu, Rongzeng Liu, Yu-Long Xie, Mei Lin, Rou Jiang, Xiong Zou, Chao Lin, Pei Yu Huang, Xi Ding, Rui You, Yi-Jun Hua, Zhi-Qiang Wang, … Rui Sun. (2021). Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial. Journal for ImmunoTherapy of Cancer, 9(11).
Chicago
Qi Yang, Yan-Feng Ouyang, Si-Yuan Chen, Yong-Long Liu, Meng-Xia Zhang, Chong-yang Duan, Ming-Yuan Chen, et al. 2021. “Toripalimab plus Intensity-Modulated Radiotherapy for Recurrent Nasopharyngeal Carcinoma: An Open-Label Single-Arm, Phase II Trial.” Journal for ImmunoTherapy of Cancer 9 (11). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....848e5f2ea76b4892f9bc4910a90c71ee&authtype=sso&custid=ns315887.